as A good SLIDE PLASE mAKE A pRESENTATION ON C-kANT 4MG **Slide 1 Content** * **Header:** * C-Kast® (Montelukast Sodium) * Tablets 10 mg / 5 mg (Chewable) * 24-hours relief against Asthma and Allergic Rhinitis * **Global Recommendation:** * **GINA 2024:** Recommends leukotriene receptor antagonist (montelukast) as an alternative controller option in steps 2 for the asthma patients 12+ years and as an add-on therapy. * **ARIA:** Guidelines recommends the use of LTRA in mild to moderate severe intermittent and persistent allergic rhinitis symptoms. * **NAEPP:** Guidelines recommends use of LTRA as alternative option in step 3 & 4 in persistent asthma. * **Clinical Findings:** * A study performed in 681 patients aged over 15 years showed that **C-Kast®** (montelukast 10 mg once daily) **REDUCED**: * Nocturnal Awakening * Daytime Asthma Symptoms * β-agonist use * Eosinophil Counts * In a trial carried out in children aged 6 to 14 with mild to moderate asthma, **C-Kast®** (montelukast 5 mg once daily) increased morning $\text{FEV}_1$ compared with placebo. * Significant improvements in all quality of life domains (**Symptoms**, **Activity**, **Environment**, **Emotion**) occurred with **C-Kast®** (montelukast) treatment. --- **Slide 2 Content** * **Header:** * C-Kast® (Montelukast Sodium) | 10 mg & 5 mg (Chewable) * 24-hours relief against Asthma and Allergic Rhinitis * **Clinical Effectiveness & Safety:** * Clinical effectiveness and safety of montelukast in asthma. * LTRAs can be used as a monotherapy or as an add-on therapy in addition to ICS. They may be an effective alternative in asthma control and safe even with long-term usage. The advantages of LTRAs include low risks of side effects and rapid onset of action and achievement of peak effect. * **Efficacy Metrics:** * Highly Effective in improving quality of life of Adults with Asthma & Allergic Rhinitis. * Treatment with 10 mg montelukast **86.5%** ($n=4547$) of patients reported a strong or marked improvement in day-time asthma symptoms and **88.5%** ($n=4367$) reported improvement in night-time symptoms. * High proportion of patients had a strong or marked improvement in all symptoms of allergic rhinitis: * **78%** Burning Eyes * **78%** Watery Eyes * **79%** Nasal Congestion * **81%** Rhinorrhea * **84%** Sneezing, Itching * **Branding:** Chiesi | Tutti Frutti flavor callout --- **Slide 3 Content** * **Header/Tagline:** * Add ON to * Keep ON * **Product Details:** * C-Kast® (Montelukast Sodium) * 5 mg & 10 mg Tablets * Tutti Frutti flavor * Chiesi logo
as A good SLIDE PLASE mAKE A pRESENTATION ON C-kANT 4MG
**Slide 1 Content**
* **Header:**
* C-Kast® (Montelukast Sodium)
* Tablets 10 mg / 5 mg (Chewable)
* 24-hours relief against Asthma and Allergic Rhinitis
* **Global Recommendation:**
* **GINA 2024:** Recommends leukotriene receptor antagonist (montelukast) as an alternative controller option in steps 2 for the asthma patients 12+ years and as an add-on therapy.
* **ARIA:** Guidelines recommends the use of LTRA in mild to moderate severe intermittent and persistent allergic rhinitis symptoms.
* **NAEPP:** Guidelines recommends use of LTRA as alternative option in step 3 & 4 in persistent asthma.
* **Clinical Findings:**
* A study performed in 681 patients aged over 15 years showed that **C-Kast®** (montelukast 10 mg once daily) **REDUCED**:
* Nocturnal Awakening
* Daytime Asthma Symptoms
* β-agonist use
* Eosinophil Counts
* In a trial carried out in children aged 6 to 14 with mild to moderate asthma, **C-Kast®** (montelukast 5 mg once daily) increased morning $\text{FEV}_1$ compared with placebo.
* Significant improvements in all quality of life domains (**Symptoms**, **Activity**, **Environment**, **Emotion**) occurred with **C-Kast®** (montelukast) treatment.
---
**Slide 2 Content**
* **Header:**
* C-Kast® (Montelukast Sodium) | 10 mg & 5 mg (Chewable)
* 24-hours relief against Asthma and Allergic Rhinitis
* **Clinical Effectiveness & Safety:**
* Clinical effectiveness and safety of montelukast in asthma.
* LTRAs can be used as a monotherapy or as an add-on therapy in addition to ICS. They may be an effective alternative in asthma control and safe even with long-term usage. The advantages of LTRAs include low risks of side effects and rapid onset of action and achievement of peak effect.
* **Efficacy Metrics:**
* Highly Effective in improving quality of life of Adults with Asthma & Allergic Rhinitis.
* Treatment with 10 mg montelukast **86.5%** ($n=4547$) of patients reported a strong or marked improvement in day-time asthma symptoms and **88.5%** ($n=4367$) reported improvement in night-time symptoms.
* High proportion of patients had a strong or marked improvement in all symptoms of allergic rhinitis:
* **78%** Burning Eyes
* **78%** Watery Eyes
* **79%** Nasal Congestion
* **81%** Rhinorrhea
* **84%** Sneezing, Itching
* **Branding:** Chiesi | Tutti Frutti flavor callout
---
**Slide 3 Content**
* **Header/Tagline:**
* Add ON to
* Keep ON
* **Product Details:**
* C-Kast® (Montelukast Sodium)
* 5 mg & 10 mg Tablets
* Tutti Frutti flavor
* Chiesi logo
Created using ChatSlide
C-Kast® offers 24-hour respiratory relief with Montelukast chewables in 10 mg and 5 mg doses, aligning with GINA, ARIA, and NAEPP guidelines to reduce asthma symptoms. Clinical evidence shows adults experience fewer awakenings and less rescue medication use, while children see improved morning FEV1 compared to placebo, with rhinitis symptom improvement of 78%-84%. It can be used as monotherapy or alongside inhaled corticosteroids, featuring a rapid onset and a long-term safety profile, all in...